Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Tessari, Anna; Pilla, Lorenzo; Damian, Silvia; Duca, Matteo; Paolini, Biagio; Carcangiu, Maria Luisa; Mariani, Luigi; Braud, Filippo G. De; Cresta, Sara

doi:10.1016/j.breast.2018.08.106

Cited by 25 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study results showed that TN breast cancers frequently display a higher expression of WT1 and NY-ESO-1 antigens, corroborating the results of other studies that demonstrated a reduced expression of these antigens in ER-positive breast cancers as compared to TN tumors [18e22, 28,29]. Conversely, in our work we did not find significant differences in terms of PRAME expression in TN tumors as compared to other breast cancer subtypes, as suggested in previous studies [30]. Such discrepancy can be partially explained by the use of monoclonal antibodies that bind different epitopes of PRAME and WT1 antigens.…”

Section: Discussionsupporting

confidence: 93%

Expression of tumor-associated antigens in breast cancer subtypes

et al. 2020

View full text Add to dashboard Cite

Objectives: Tumor-associated antigens (TAAs) are frequently overexpressed in several cancer types. The aim of this study was to investigate the expression of TAAs in breast cancer. Material and methods: A total of 250 selected invasive breast cancers including 50 estrogen receptor (ER)-positive (Luminal B like), 50 triple-negative (TN), 50 ER-positive lobular type, 50 ER-and progesterone receptor (PgR)-positive (Luminal A like) and 50 cerbB2-positive breast cancers, were assessed for New York esophageal squamous cell carcinoma-1 (NY-ESO-1), Wilms tumor antigen (WT-1) and PReferentially expressed Antigen of MElanoma (PRAME) antigen expression by immunohistochemistry (IHC). Results: A significantly higher expression of cancer testis (CT)-antigens NY-ESO-1 and WT-1 antigen was detected in TN breast cancers compared with ER-positive tumors. NY-ESO-1 overexpression (score 2 þ and 3þ) assessed by monoclonal and polyclonal antibodies was detected in 9 (18%) TN cancers as compared to 2 (4%) ER-positive tumors (p ¼ 0.002). WT1 over-expression (score 2 þ and 3þ) was confirmed in 27 (54%) TN tumor samples as compared to 6 (12%) ER-positive (p < 0.0001). PRAME overexpression (score 2 þ and 3þ) was detected in 8 (16%) HER2 positive tumor samples as compared to no TN and ER-positive cancers (p ¼ 0.0021). Conclusions: NY-ESO-1 and WT1 antigens are overexpressed in TN breast cancers. Because of the limited therapeutic options for this patient subgroup, CT antigen-based vaccines might prove to be useful for patients with this phenotype of breast cancer.

show abstract

Section: Discussionsupporting

confidence: 93%

Expression of tumor-associated antigens in breast cancer subtypes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…1,28,29 Similarly, breast carcinoma has been found to express PRAME in 27% to 90% of cases, but again with a cytoplasmic expression pattern. 1,3,30 Another tumor type known to have PRAME expression is renal cell carcinoma, with a range of 40% to 61% of cases positive. 1,31,32 The implications for treatment in light of the high level of PRAME expression in metastatic melanoma are significant.…”

Section: Discussionmentioning

confidence: 99%

“…For example, PRAME has been reported in 39% to 100% of head and neck squamous cell carcinomas, although it predominantly shows aberrant cytoplasmic expression by IHC as compared to the nuclear expression in melanoma 1,28,29 . Similarly, breast carcinoma has been found to express PRAME in 27% to 90% of cases, but again with a cytoplasmic expression pattern 1,3,30 . Another tumor type known to have PRAME expression is renal cell carcinoma, with a range of 40% to 61% of cases positive 1,31,32 .…”

Section: Discussionmentioning

confidence: 99%

PRAME expression in 155 cases of metastatic melanoma

2020

View full text Add to dashboard Cite

Background: PRAME (preferentially expressed antigen in melanoma) is a promising immunohistochemical marker in distinguishing benign from malignant primary cutaneous melanocytic lesions and lymph node deposits. We hypothesize that PRAME may also reliably identify melanoma metastases that are clinically detected in skin, lymph nodes, or small intestine. Methods: A total of 155 cases of metastatic melanoma to lymph node (N = 54) and non-lymph node (N = 101) sites were stained with an antibody against PRAME. Nuclear expression was scored in tumor cells as negative, 1% to 25% (1+), 26% to 50% (2+), 51% to 75% (3+), or 76% to 100% (4+). Results: PRAME expression was seen in 151/155 (97.4%) cases, with 4+ expression in 64 cases (41.3%), 3+ expression in 46 cases (29.7%), 2+ expression in 18 cases (11.6%), and 1+ expression in 23 cases (14.8%). Lymph node metastases were more likely to show lower expression as compared to metastases to other anatomic sites (P = 0.003). Conclusions: A high level of PRAME immunoreactivity was identified in this cohort of metastatic melanoma. Lymph node metastases showed more focal or absent PRAME expression as compared to metastases to other sites. Overall, PRAME is a useful tool for confirming the diagnosis of melanoma in a metastatic setting, in both nodal and visceral deposits.

show abstract

“…Globally, there were approximately 2.1 million newly diagnosed cases of female breast cancer in 2018, accounting for a quarter of cancer cases in females . The PRAME antigen is expressed widely among diverse breast cancer subtypes, including hormone‐sensitive tumours . Moreover, PRAME expression is involved in poor clinical outcome and is useful in conjunction with clinical parameters to predict breast cancer outcomes .…”

Section: Role Of Prame In Cancersmentioning

confidence: 99%

“…24 The PRAME antigen is expressed widely among diverse breast cancer subtypes, including hormone-sensitive tumours. 25,26 Moreover, PRAME expression is involved in poor clinical outcome and is useful in conjunction with clinical parameters to predict breast cancer outcomes. 16,27 Notably, the expression level of PRAME is correlated with negative oestrogen receptor status, lower rates of overall survival and elevated rates of distant metastases.…”

Section: Breast Cancermentioning

confidence: 99%

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Zou

Wang

et al. 2020

Cell Proliferation

View full text Add to dashboard Cite

Preferentially expressed antigen in melanoma (PRAME), which belongs to the cancer/testis antigen (CTA) gene family, plays a pivotal role in multiple cellular processes and immunotherapy response in human cancers. PRAME is highly expressed in different types of cancers and is involved in cell proliferation, apoptosis, differentiation and metastasis as well as the outcomes of patients with cancer. In this review article, we discuss the potential roles and physiological functions of PRAME in various types of cancers. Moreover, this review highlights immunotherapeutic strategies that target PRAME in human malignancies. Therefore, the modulation of PRAME might be useful for the treatment of patients with cancer.

show abstract

Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Cited by 25 publications

References 39 publications

Expression of tumor-associated antigens in breast cancer subtypes

Expression of tumor-associated antigens in breast cancer subtypes

PRAME expression in 155 cases of metastatic melanoma

The role of the cancer testis antigen PRAME in tumorigenesis and immunotherapy in human cancer

Contact Info

Product

Resources

About